174 related articles for article (PubMed ID: 19403560)
1. The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.
Ota S; Zhou ZQ; Link JM; Hurlin PJ
Hum Mol Genet; 2009 Jul; 18(14):2609-21. PubMed ID: 19403560
[TBL] [Abstract][Full Text] [Related]
2. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.
Park J; Kim SY; Kim HJ; Kim KM; Choi EY; Kang MS
Oncotarget; 2016 May; 7(19):28670-83. PubMed ID: 27107424
[TBL] [Abstract][Full Text] [Related]
3. c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.
Liu H; Ai J; Shen A; Chen Y; Wang X; Peng X; Chen H; Shen Y; Huang M; Ding J; Geng M
Clin Cancer Res; 2017 Feb; 23(4):974-984. PubMed ID: 27401245
[No Abstract] [Full Text] [Related]
4. The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs.
Tesfaye E; Martinez-Terroba E; Bendor J; Winkler L; Olivero C; Chen K; Feldser DM; Zamudio JR; Dimitrova N
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326251
[TBL] [Abstract][Full Text] [Related]
5. MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts.
Zhang F; Zakaria SM; Högqvist Tabor V; Singh M; Tronnersjö S; Goodwin J; Selivanova G; Bartek J; Castell A; Larsson LG
Cell Cycle; 2018; 17(24):2697-2715. PubMed ID: 30526305
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
Kwak Y; Cho H; Hur W; Sim T
Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
8. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line.
Zongaro S; de Stanchina E; Colombo T; D'Incalci M; Giulotto E; Mondello C
Cancer Res; 2005 Dec; 65(24):11411-8. PubMed ID: 16357149
[TBL] [Abstract][Full Text] [Related]
9. FGFR2 mutations in bent bone dysplasia syndrome activate nucleolar stress and perturb cell fate determination.
Neben CL; Tuzon CT; Mao X; Lay FD; Merrill AE
Hum Mol Genet; 2017 Sep; 26(17):3253-3270. PubMed ID: 28595297
[TBL] [Abstract][Full Text] [Related]
10. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
Tanizaki J; Ercan D; Capelletti M; Dodge M; Xu C; Bahcall M; Tricker EM; Butaney M; Calles A; Sholl LM; Hammerman PS; Oxnard GR; Wong KK; Jänne PA
Cancer Res; 2015 Aug; 75(15):3139-46. PubMed ID: 26048680
[TBL] [Abstract][Full Text] [Related]
11. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
Katoh Y; Katoh M
Int J Mol Med; 2009 Mar; 23(3):307-11. PubMed ID: 19212647
[TBL] [Abstract][Full Text] [Related]
12. Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence.
Patel PL; Suram A; Mirani N; Bischof O; Herbig U
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5024-33. PubMed ID: 27503890
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
[TBL] [Abstract][Full Text] [Related]
15. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
16. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
17. Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells.
Choi JW; Schroeder MA; Sarkaria JN; Bram RJ
Cancer Res; 2014 Jan; 74(2):484-96. PubMed ID: 24272483
[TBL] [Abstract][Full Text] [Related]
18. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
19. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
20. FGFR and PTEN signaling interact during lens development to regulate cell survival.
Chaffee BR; Hoang TV; Leonard MR; Bruney DG; Wagner BD; Dowd JR; Leone G; Ostrowski MC; Robinson ML
Dev Biol; 2016 Feb; 410(2):150-163. PubMed ID: 26764128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
